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Consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT) provides a survival beneﬁt
to patients with acute lymphoblastic leukemia (ALL). We have previously reported comparable survival and
relapse rates after T celledepleted (TCD) allo-HSCT compared with unmodiﬁed transplantations for acute
myelogenous leukemia, myelodysplastic syndrome, and non-Hodgkin lymphoma with signiﬁcantly decreased
graft-versus-host disease (GVHD). We performed a 56-patient retrospective study to evaluate TCD allo-HSCT
for the treatment of ALL after myeloablative total body irradiationebased therapy. The 2-year and 5-year
overall survival rates for patients with ALL after TCD allo-HSCT were 0.39 (95% conﬁdence interval [CI],
0.26-0.52) and 0.32 (95% CI, 0.19-0.44), respectively, and the 2-year and 5-year disease-free survival rates
were 0.38 (95% CI, 0.25-0.50) and 0.32 (95% CI, 0.20-0.44). There was a trend toward improved survival of
patients who underwent TCD allo-HSCT in ﬁrst complete remission compared with those who did so in other
remission states. The cumulative incidence of grade II-IV acute GVHD at 1 year was 0.20 (95% CI, 0.10-0.31),
and no patients developed grade IV acute GVHD. The cumulative incidence of chronic GVHD in 41 evaluable
patients at 2 and 5 years was 0.15 (95% CI, 0.04-0.26), and that of extensive chronic GVHD at 2 and 5 years was
0.05 (95% CI, 0-11.6). We demonstrate OS and DFS rates that compare favorably to unmodiﬁed allo-HSCT with
lower rates of GVHD.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION 7 published studies of patients with ALL reported a signiﬁ-
Approximately one-third of the nearly 4000 cases of acute
lymphoblastic leukemia (ALL) occurring annually in the
United States affect adults [1]. Although rates of complete
remission (CR) after induction and consolidation are nearly
equivalent in adults (>78%) and children (>90%), the overall
cure rate is only <40% in adults, compared with 80% in
children [1]. Patients with relapsed or refractory disease have
a dismal prognosis, with a median survival of 6 months [2-4].
Numerous previous studies have demonstrated the beneﬁt
of allogeneic hematopoietic stem cell transplantation (allo-
HSCT) in patients with ALL in second CR (CR2) or high-risk
ﬁrst CR (CR1) [5-10]. Other studies have not reported
a similar beneﬁt, however [11,12]. A recent meta-analysis ofedgments on page 212.
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patients compared with transplants from nonsibling donors
[13]. More recent studies also have demonstrated the beneﬁt
of allo-HSCT in patients with standard-risk ALL [14,15].
We have established the efﬁcacy of T celledepleted (TCD)
allo-HSCT as postremission therapy in patients with acute
myelogenous leukemia, myelodysplastic syndrome, or
non-Hodgkin lymphoma, including an almost complete
elimination of graft-versus-host disease (GVHD) without
compromising the antileukemic efﬁcacy of the allograft
[16-19]. Here we report the results of a single-center retro-
spective review of 56 adult patients with ALL who under-
went TCD allo-HSCT, which found acceptable overall survival
(OS) and disease-free survival (DFS) with a low risk of GVHD.PATIENTS AND METHODS
Patients
Fifty-six consecutive adult patients with ALL underwent allogeneic TCD
allo-HSCT at Memorial Sloan-Kettering Cancer Center between May 1997
and December 2008. Written informed consent for treatment was obtainedTransplantation.
Table 1
Patient Characteristics
Age, years, median (range) 36 (18-63)
Age group, years, n
<20 7
20-29 16
30-39 7
40-49 15
>50 11
Cytogenetics at diagnosis, n*
Good risk 3
Standard risk 25
Poor risk 24
Not evaluable/unknown 4
Phenotype, n
B 45
T 9
Multilineage/unknown 2
Extramedullary disease, n
Yes 16
No 40
Donor, n
Matched related 22
Mismatched related 6
Matched unrelated 15
Mismatched unrelated 13
Status at HSCT, n
CR1 27
CR2 18
CR3þ 11
Conditioning regimen, n
HFTBI/thiotepa/cyclophosphamide 18
HFTBI/thiotepa/ﬂudarabine 38
* Good risk: hyperdiploidy, del(9p); poor risk: Phþ, t(4;11), t(8;14),
complex karyotype (5 abnormalities), hypodiploidy/near triploidy; stan-
dard risk: other [26].
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obtained from the center’s Institutional Review and Privacy Board. Eligibility
criteria for transplantation included a diagnosis of relapsed or refractory ALL
or high-risk ALL in CR1, age <65 years, availability of an HLA-matched or
single-allele-mismatched donor, absence of active infection, and lack of
coexisting cardiac, pulmonary, hepatic, or renal dysfunction that would
preclude administration of the cytoreductive regimen. HLA matching was
established by DNA sequence-speciﬁc oligonucleotide typing for HLA-A, -B,
-C, -DRB1, and -DQB1 loci.
Transplantation Procedure and Supportive Care
All patients received myeloablative cytoreduction comprising hyper-
fractionated total body irradiation (HFTBI), followed by thiotepa and high-
dose cyclophosphamide (18 patients) or thiotepa and ﬂudarabine (38
patients) [16,17,19]. Patients received the ﬂudarabine regimen on a protocol
designed to study whether the additional immune suppression from ﬂu-
darabine could eliminate the need for antithymocyte globulin (ATG) in TCD
allo-HSCT using related donors [17]. Otherwise, patients received a cyclo-
phosphamide-based regimen. HFTBI (total dose of 1375 cGy or 1500 cGy,
with lung blocking plus chest wall and testicular boosts) was administered
as described previously [16]. After HFTBI, thiotepa 5 mg/kg i.v. was admin-
istered daily for 2 days. In the 18 patients who received the former regimen,
administration of thiotepa was followed by high-dose cyclophosphamide
60 mg/kg i.v. daily for 2 days [16]. In the other 38 patients, ﬂudarabine
25 mg/m2 i.v. was administered daily for 5 days beginning on the ﬁrst day of
thiotepa administration [17].
T cells were removed from bone marrow (BM) grafts by sequential
soybean lectin agglutination and sheep RBC rosette depletion [16,20]. T cell
depletion of granulocyte colony-stimulating factoremobilized peripheral
blood stem cells (PBSCs) was accomplished by positive selection of CD34þ
stem cells using the ISOLEX 300i Magnetic Cell Separator and subsequent
sheep RBC rosette depletion [17]. TCD BM or PBSCs were infused within
24-48 hours after completion of chemotherapy. Seventeen patients received
BM, and 38 received PBSCs, all of which were TCD. One patient received
a combined TCD BM and PBSC allograft.
Recipients of an HLA-matched related donor graft whowere treatedwith
HFTBI, thiotepa, andﬂudarabine (n¼11), and2patients age<20years didnot
receive any rejectionprophylaxis. Equine (30mg/kg/dose) or rabbit (5mg/kg/
dose) ATG before (n ¼ 30) or after (n ¼ 13) stem cell infusion provided graft
rejection prophylaxis in all other patients [16,17,21]. Patients who received
2 daily doses of ATG before stem cell infusion were given high-dose methyl-
prednisolone (1 mg/kg/day) with each dose. The patients who received
4dosesofATGafter stemcell infusion receivedmethylprednisolonewitheach
dose of ATG, with steroids rapidly tapered. All patients received supportive
care and prophylaxis against opportunistic infections in accordance with
standard guidelines. No pharmacologic GVHD prophylaxis was given.
Myeloid engraftment was deﬁned as an absolute neutrophil count
(ANC) >500/mL on 3 consecutive days posttransplantation. Platelet
engraftment was deﬁned as an untransfused platelet count >20,000/mL for
at least 3 consecutive days. Primary graft failure was deﬁned as the absence
of neutrophil recovery (ANC 500/mL) by day 28 and BM biopsy with 5%
cellularity. Secondary graft failure was deﬁned as ANC <500/mL after
primary engraftment, with BM biopsy showing 5% cellularity [18]. GVHD
was diagnosed clinically, conﬁrmed pathologically by biopsy whenever
possible, and classiﬁed according to standard criteria [22]. Patients who
engraftedwere evaluable for acute GVHD (aGVHD), and patients surviving at
least 100 days were evaluable for chronic GVHD (cGVHD) [23]. Cause of
death was determined using a standard algorithm [24].
Data Collection and Statistical Methods
Analyses were performed as of December 31, 2011. OS and DFS proba-
bilities were calculated using the Kaplan-Meier method, and the differences
between levels within a covariate were tested using log-rank statistics [25].
The cumulative incidence of relapse (CIR) was calculated using competing-
risk methods. The following pretransplantation variables were assessed for
theireffectsonOSandDFS:disease status, cytogenetic risk stratiﬁcation (high,
standard, or low) [26], presence of extramedullary disease, stem cell source,
HLAmatch, and use of a cyclophosphamide-containing versus a ﬂudarabine-
containing preparative regimen. Univariate analyses were performed using
the log-rank test. Because only one association between pretransplantation
variables and survival endpoints reached statistical signiﬁcance in the
univariate analyses, multivariate analysis was not performed.
RESULTS
Patient Characteristics
Pretransplantation characteristics of the 56 patients are
summarized in Table 1. The median age was 36 years, and 11patients were age >50 years. Twenty-nine patients (52%)
underwent transplantation in CR1 or greater, with 11
patients (20%) in third CR (CR3) or greater. Almost one-half
(43%) of the patients had poor-risk cytogenetics. A signiﬁcant
number of patients received an alternative donor graft, with
28 (50%) receiving an unrelated donor graft (13 mismatched)
and 6 receiving a mismatched related donor graft (ie, not
matched at 10/10 alleles).Engraftment and GVHD
All 54 patients evaluable for engraftment achieved initial
engraftment. However, 2 patients who received a mis-
matched graft from an unrelated donor experienced
secondary graft failure, one at day þ35 and the other at
day þ67. Both patients eventually died with multiorgan
failure. The median time to neutrophil engraftment was 13
days for the entire cohort, 15 days for recipients of BM grafts,
and 12 days for recipients of PBSC grafts. The median time to
platelet engraftment was 14 days for the entire cohort, 25
days for BM recipients, and 13 days for PBSC recipients. Four
patients (2 BM recipients and 2 PBSC recipients) did not
achieve platelet engraftment. Data on engraftment times
were not available for 2 patients (both BM recipients), and 2
patients (both PBSC recipients) were not evaluable for
engraftment because of early death.
The cumulative incidence of grade II-IV aGVHD at 1 year
in the 54 evaluable patients was 0.20 (95% conﬁdence
interval [CI], 0.10-0.31; Figure 1A). No patient developed
grade IV aGVHD. The organs involved included skin only in
7 patients, skin and gastrointestinal tract in 2 patients,
gastrointestinal tract only in 1 patient, and skin and liver in 1
patient. Two of the patients with aGVHD received a BM or
Figure 1. Cumulative incidence of aGVHD (A) and cGVHD (B).
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received a BM or PBSC graft from an alternative donor
(4 from amatched unrelated donor and 5 from amismatched
related or unrelated donor). The cumulative incidence of
cGVHD in 41 evaluable patients at 2 and 5 years was 0.15
(95% CI, 0.04-0.26; Figure 1B), and that of extensive cGVHD at
2 and 5 years was 0.05 (95% CI, 0-11.6).Donor Leukocyte Infusion
Four patients received unselected donor lymphocyte
infusion (DLI) after their initial transplantation, and 1 patient
received Epstein-Barr virus (EBV) cytotoxic T lymphocytes.
DLI was administered for infection in 2 patients, for minimal
residual disease in 1 patient, and for mixed BM chimerism in
1 patient who later developed cGVHD and died.Reactivation of Cytomegalovirus and EBV
Thirty patients had documented cytomegalovirus (CMV)-
positive serology. Of the 28 patients evaluable for viral
reactivation (minus 2 premature deaths), 9 (32%) had CMV
reactivation. One of these patients died from CMV pulmo-
nary disease. Of 40 patients who were surveilled with EBV
PCR, 7 (18%) had evidence of EBV reactivation. Four of these
patients required therapy with rituximab. One other patient,
who underwent transplantation before routine EBV PCR
surveillance testing, had an EBV lymphoproliferative
disorder detected on lung biopsy analysis and received DLI
and rituximab.Nonrelapse Mortality
Causes of death in our cohort included infection in 10
patients, GVHD in 8 patients, organ failure in 5 patients, and
nonengraftment in 2 patients, both of whom had evidence of
reemergent host cells on BM evaluation. Of the 10 patients
who died of infection, 5 had a documented bacterial infec-
tion (4 with vancomycin-resistant enteroccocci [VRE] and 1
with Clostridium difﬁcile colitis), and 3 had a documented
viral infection (1 patient each with CMV, EBV, and adeno-
virus). Three of the 4 patients who died with VRE infection
were noted to have VRE colonization before transplantation,
and the fourth patient underwent transplantation before
institution of routine VRE surveillance. We previously
described the virulence of VRE in unmodiﬁed and TCD
allo-HSCT [27]. One patient eachwas diagnosedwith a fungal
infection (Aspergillus ﬂavus) and toxoplasmosis. Of the
5 patients with fatal organ failure, 4 died from pulmonary
toxicity and 1 died from veno-occlusive disease. All 4
patients who died from pulmonary toxicity suffered
progressive pulmonary failure that culminated in acute
respiratory distress syndrome. Seven of the 8 patients with
fatal GVHD died from infection in the setting of immuno-
suppressive treatment (1 with bacterial infection, 3 with
fungal infection, 2 with viral infection, and 1 with toxo-
plasmosis). The eighth patient had biopsy-proven GVHD
and died of concurrent demyelination; however, he was
classiﬁed as dying from GVHD based on the algorithm of
Copelan et al. [24].
The nonrelapse mortality (NRM) at 2 years was signiﬁ-
cantly higher for patients who underwent allo-HSCT in CR3þ
compared with those who did so in CR1 or CR2 (0.63 versus
0.33; P ¼ .030). Eight of the 11 patients undergoing trans-
plantation in CR3þ died from a transplantation-related
cause, resulting in an 2-year NRM rate of 0.39 for the entire
cohort. Because the mortality rate fromGVHD-related causes
differed from our previous data on TCD allo-HSCT [16-19], we
evaluated GVHD-related mortality and NRM not related to
GVHD by disease status. We found that the 2-year NRM
without GVHD was related to disease status (CR1, 0.19;
CR2, 0.28; CR3þ, 0.55; P ¼ .089), whereas GVHD-related
mortality was not (P ¼ .569).CIR, DFS, and OS
The CIR for the entire cohort was 0.23, and was not
affected by disease status (P ¼ .522) or cytogenetic risk
group (P ¼ .408). With a median follow-up of 6.1 years, the
entire cohort had a 2-year DFS of 0.38 (95% CI, 0.25-0.50),
a 5-year DFS of 0.32 (95% CI, 0.20-0.44) (Figure 2A), a 2-year
of 0.39 (95% CI, 0.26-0.52), and a 5-year OS of 0.32 (95% CI,
0.19-0.44) (Figure 2B). Data on 2-year and 5-year DFS
and OS by disease status are presented in Table 2. Patients
in CR1 had a higher DFS (P ¼ .062; Figure 2C) and OS (P ¼
.056; Figure 2D) than those in CR2þ. Analysis of pre-
transplantation prognostic factors revealed a higher median
OS (P ¼ .041) and a trend toward improved DFS (P ¼ .051) in
patients with a matched related donor compared with those
with other donors. No differences in either DFS or OS were
seen based on cytogenetic risk group, presence of extra-
medullary disease, or age at transplantation. In addition, no
differences in DFS or OS were found based on cytoreduction
regimen (HFTBI-thiotepa-cyclophosphamide versus HFTBI-
thiotepa-ﬂudarabine) or graft source, as reported previ-
ously in patients with non-Hodgkin lymphoma treated with
the same approach [19].
Figure 2. DFS (A) and OS (B) for the entire cohort and DFS (C) and OS (D) by disease status.
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Our results represent the ﬁrst published report of ex vivo
TCD allo-HSCT for the treatment of ALL in adults without
posttransplantation pharmacologic GVHD prophylaxis.
Recognizing the limitations of a retrospective study that
encompasses many years, we nevertheless have demon-
strated acceptable OS, DFS, and relapse rate with low rates of
GVHD in the context of the historical experience with
T cellereplete allo-HSCT [5-10]. Notably, our results for
patients in CR1 are promising, with a plateau in the OS and
DFS curves for these patients at approximately 2 years.
Fifty-six adult patients underwent TCD allo-HSCT for the
treatment of ALL. This patient population was particularly
high risk, with only 7 patients age <20 years and 24 patientsTable 2
OS and DFS by Disease Status
2-Year 5-Year
CR1
OS 0.48 (0.29-0.67) 0.48 (0.29-0.67)
DFS 0.48 (0.29-0.67) 0.48 (0.29-0.67)
CR2
OS 0.39 (0.16-0.61) 0.22 (0.03-0.41)
DFS 0.33 (0.12-0.55) 0.22 (0.03-0.41)
CR3þ
OS 0.18 (0-0.41) 0.09 (0-0.26)
DFS 0.18 (0-0.41) 0.09 (0-0.26)with poor-risk cytogenetic classiﬁcation (43%). Slightly more
than one-half of the patients (29; 52%) underwent trans-
plantation in >CR1. Sixteen patients (29%) had extra-
medullary disease at presentation. For the entire cohort, the
2-year OS of 0.39 and 2-year DFS of 0.38 were comparable to
previous data on T cellereplete transplantation in this high-
risk patient population. For patients in CR1, OS and DFS were
0.48 at both 2 years and 5 years. In the absence of post-
transplantation pharmacologic GVHD prophylaxis, the
cumulative incidence of aGVHD at 1 year was only 0.20 (with
no incidence of grade IV aGVHD), consistent with our
previous data on TCD allo-HSCT, despite the fact that 34% of
the patients received a mismatched donor graft. The inci-
dence of cGVHDwas only 15% at 2 years posttransplantation.
The 2-year NRM of 0.39 for the entire cohort is higher
than our previous ﬁndings for TCD allo-HSCT in other
diseases [16-18], with infection the most prevalent
nonerelapse-related cause of death. Five of the 10 deaths
attributed to infection resulted from early bacterial infec-
tions (range, day þ5 to day þ66), 4 of which due to VRE
bacteremia; thus, it is difﬁcult to attribute these deaths to
TCD of the graft. Furthermore, we have previously demon-
strated that the risk of VRE bloodstream infections is not
increased by TCD [27]. The increased NRM associated with
disease status at allo-HSCT suggests that heavy pretreatment
of patients, especially those with advanced disease, was
a likely contributor to NRM. In addition, although OS and DFS
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further suggesting that the degree of pretreatment may
contribute to post-HSCT outcomes in these patients. Another
striking ﬁnding is the 8 deaths due to GVHD in the context of
a lowoverall prevalence of GVHD, an expected distribution of
involved organs, and no incidence of grade IV GVHD. This
high mortality attributable to GVHD also contrasts with our
previous experiences with TCD [16-18]. It is possible that the
signiﬁcant treatment before transplantation in our cohort
(and in patients with ALL in general), including extensive
exposure to glucocorticoids, led to increased susceptibility to
complications of GVHD and its immunosuppressive treat-
ments. Of note, GVHD-related mortality was apparently not
related to disease status. This ﬁnding may be related to the
small number of patients who experienced GVHD after TCD
allo-HSCT, or may imply that the common use of steroids or
some other pretransplantation characteristic other than the
amount of pretreatment increases the risk of complications
associated with GVHD and its therapy for patients with ALL.
Certain interventions that could potentially decrease the
NRM for patients with ALL undergoing TCD allo-HSCT. First,
acknowledging the small size of our CR3þ group, a reduced-
intensity conditioning approach could be offered to patients
withALL in>CR2, given the high rate of NRM in these patients
with the intense regimens required for TCD. In addition,
preemptive use of antibiotics active against VRE for colonized
patients could be considered. Alternative nontransplantation
options also may be explored for patients in >CR2.
We compared our experience with TCD allo-HSCT with
other published experiences with T cellereplete allo-HSCT
for ALL. Goldstone et al. [14] recently published the largest
randomized study of adult ALL in the MRC UKALL XII/ECOG
E2993 trial. A donor versus no-donor analysis of Philadelphia
chromosome (Ph)-negative patients in CR1 revealed a 5-year
OS of 53% in patients with a donor. Thomas et al. [8] studied
the optimal postinduction therapy for patients in CR1 in the
LALA-94 trial. High-risk patients were assigned to undergo
allo-HSCT when an HLA-identical sibling was identiﬁed.
High-risk Ph- patients who underwent allo-HSCT (without
central nervous system disease) had a 5-year DFS of 44% and
a 5-year OS of 51%, and Phþ patients had a 3-year DFS of 34%
and a 3-year OS of 36%. Our 5-year OS of 48% in the present
study compares quite favorably with these ﬁndings, espe-
cially given that 16 (59%) of our patients in CR1 were Phþ.
Outcome data for patients who underwent allo-HSCT
in >CR1 are more limited. However, it appears that survival
outcomes are comparable in TCD allo-HSCT and T celle
replete strategies in this patient population. In an analysis
of allo-HSCT recipients who relapsed after their initial
therapy in the MRC UKALL XII/ECOG E2993 trial, Fielding
et al. [2] found a 5-year OS of 23% in recipients of matched
related donor transplants and 16% in recipients of matched
unrelated donor transplants.
We previously reported that certain patient populations
can have favorable survival after TCD allo-HSCT with a
decreased risk of GVHD in the absence of posttransplantation
pharmacologic prophylaxis [16-19]. A recent cooperative
group-led multicenter trial of ex vivo TCD allo-HSCT in
patients with acute myelogenous leukemia in CR1 or CR2
supports our center’s experience [28]. The risk of grade II-IV
aGVHD in the multicenter trial was comparable at 22.7%,
with only a 6.8% incidence of extensive cGVHD at 24 months
posttransplantation. Thus, TCD allo-HSCT offers appropriate
patients comparable survival along with the decreased
morbidity associated with GVHD.Our ﬁndings should be conﬁrmed prospectively, given
that this study has some limitations common to retrospec-
tive studies. We cannot rule out a selection bias. The study
encompasses many years, during which many clinical
changes have occurred. In addition, our small sample size
limits our conclusions.
In summary, this ﬁrst published experience of adult
patients who underwent TCD allo-HSCT for ALL demon-
strates survival and relapse rates that compare favorably
with those for T cellereplete transplants but, importantly,
with a lower rate of GVHD. The survival outcomes for
patients in CR1 are promising, with a plateau noted at
approximately 2 years posttransplantation. Further studies
are needed to identify subpopulations of patients with ALL
who would beneﬁt most from a TCD strategy as opposed to
a T cellereplete strategy. Patients with an advanced disease
status might have improved outcomes with a reduced-
intensity strategy. In addition, studies are needed to assess
whether the addition of posttransplantation maintenance
therapy might improve outcomes after TCD allo-HSCT in
certain patient populations. Finally, minimal residual disease
monitoring should be incorporated into future studies to
assess whether minimal residual disease affects clinical
outcomes after TCD allo-HSCT.
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